Systemic Lupus Erythematosus Management (ACR 2025)

Algorithm Steps

1. ▶

   Start

   Confirmed SLE Diagnosis

   Diagnosis per ACR/EULAR 2019 classification criteria

   1. ●

      Action

      Universal Treatment for ALL SLE Patients

      Strong recommendation

      • Hydroxychloroquine (HCQ) for ALL patients unless contraindicated
      • HCQ dose: ≤5 mg/kg actual body weight/day
      • Annual ophthalmologic screening after 5 years
      • Sun protection and vitamin D supplementation
      • Cardiovascular risk factor management
      1. ◆

         Decision

         Assess Disease Activity

         Evaluate organ involvement and severity

         • Use validated tools: SLEDAI-2K, BILAG, PGA
         • Target: Remission or LLDAS (Lupus Low Disease Activity State)
         • Consider: skin, joints, serositis, hematologic, renal, CNS
         1. ●

            Action

            Glucocorticoid Management

            Minimize use as much as possible (Strong)

            • If on prednisone >5 mg/day: TAPER to ≤5 mg/day within 6 months
            • Goal: prednisone ≤5 mg/day (ideally zero)
            • Pulse IV methylpred for severe flares (then rapid taper)
            • Add/escalate immunosuppression to enable GC reduction
            1. ⚠

               Warning

               ⚠️ Glucocorticoid Toxicity

               Strong recommendation to minimize

               • Long-term GC associated with damage accrual
               • Increased infection, osteoporosis, AVN, diabetes
               • Prednisone >5-7.5 mg/day associated with significant toxicity
               • Add immunosuppression rather than increase GC
               1. ◆

                  Decision

                  Moderate-Severe Disease?

                  Active disease despite HCQ ± mild immunosuppression

                  1. ●

                     Action

                     Conventional Immunosuppression

                     Add to HCQ background

                     • Mycophenolate mofetil (MMF): 2-3g/day
                     • Azathioprine: 2-2.5 mg/kg/day (check TPMT first)
                     • Methotrexate: 15-25 mg/week (with folic acid)
                     • Cyclophosphamide: reserved for severe organ-threatening disease
                     1. ◆

                        Decision

                        Inadequate Response to Conventional IS?

                        Failure to achieve remission/LLDAS on HCQ + IS

                        1. ●

                           Action

                           Biologic DMARDs

                           FDA-approved for SLE

                           • Belimumab (anti-BLyS): IV 10mg/kg q2wk x3 then q4wk, OR SC 200mg/wk
                           • Anifrolumab (anti-IFNAR): IV 300mg q4wk
                           • Continue HCQ and background IS with biologics
                           • May allow further GC reduction
                           1. ●

                              Action

                              Organ-Specific Considerations

                              Specialized management by manifestation

                              • Lupus nephritis: See ACR 2024 LN guideline
                              • Neuropsychiatric lupus: High-dose GC + IS, consider rituximab
                              • Hematologic (ITP, AIHA): High-dose GC, rituximab, splenectomy
                              • Pulmonary: IS per severity; plasma exchange for DAH
                              1. ●

                                 Action

                                 Refractory Disease

                                 Failed multiple therapies

                                 • Rituximab (off-label but widely used)
                                 • Voclosporin (approved for LN)
                                 • Combination biologic approaches (emerging)
                                 • Clinical trial enrollment
                                 • Specialist center referral
                                 1. ◆

                                    Decision

                                    Remission/LLDAS Achieved?

                                    Sustained for ≥6-12 months

                                    1. ✓

                                       Outcome

                                       SLE Controlled

                                       Maintain HCQ, consider cautious IS taper, regular monitoring

                                    2. ⚠

                                       Warning

                                       Specialist Center Referral

                                       Refractory disease, severe organ involvement, clinical trial

         2. ●

            Action

            Mild Disease (Skin/Joints)

            First-line for mild manifestations

            • HCQ foundation (continue)
            • Low-dose prednisone short-term if needed
            • Methotrexate for arthritis/skin
            • Topical agents for cutaneous lupus
            • NSAIDs for arthralgia (caution in renal disease)